Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial-Reference-Cited by-同舟云学术

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Published:2014-08 Issue:8 Volume:25 Page:1544-1550
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Loi S.,Michiels S.,Salgado R.,Sirtaine N.,Jose V.,Fumagalli D.,Kellokumpu-Lehtinen P.-L.,Bono P.,Kataja V.,Desmedt C.,Piccart M.J.,Loibl S.,Denkert C.,Smyth M.J.,Joensuu H.,Sotiriou C.

Funder

European Union Framework

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/8/1544/16703237/mdu112.pdf

Reference39 articles.

1. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion;Schreiber;Science,2011

2. Lymphocyte infiltrates as a prognostic variable in female breast cancer;Aaltomaa;Eur J Cancer,1992

3. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates;Alexe;Cancer Res,2007